OncoMetric Hub

Checkpoint Cost-Benefit Analyzer

Checkpoint Cost-Benefit Analyzer

Economic modeling tool for evaluating PD-1 inhibitor immunotherapy implementation in pancreatic cancer management

Patient and Disease Factors

%
mut/Mb

Economic Parameters

$
$
$
$
$
$

Treatment Parameters

months
%
%
%
%
%

Payment and Reimbursement Models

%
%
%

Cost-Benefit Analysis Results

Summary

Cost Analysis
Clinical Outcomes
Alternative Payment Models

Cost Comparison: PD-1 Inhibitor vs. Standard Treatment

Cost Category PD-1 Inhibitor Therapy ($) Standard Therapy ($) Difference ($)

Clinical Outcome Projections

Outcome Metric PD-1 Inhibitor Standard Therapy Impact

Alternative Payment Model Scenarios

Outcome-Based Pricing Model

Payment for therapy is tied to patient response. Non-responders have a 50% discount applied to therapy costs.

Bundled Care Model

All related services are bundled at a 15% discount from standard fees.

Value-Based Care Model

Incorporates quality measures and provides 10% credit for positive outcomes.

Disclaimer: This calculator provides estimates based on available data and user inputs. Results should be considered as guidance only and not as definitive financial advice.

© 2025 Checkpoint Cost-Benefit Analyzer. For educational and planning purposes only.

Checkpoint Cost-Benefit Analyzer (Pancreatic Cancer)

Checkpoint Cost-Benefit Analyzer

Provides a simplified economic model to evaluate the potential cost implications of using PD-1 inhibitor immunotherapy compared to traditional chemotherapy pathways in pancreatic cancer management, based on user-defined inputs. For illustrative and discussion purposes only.

Patient & Disease Factors

PD-1 inhibitors typically indicated for MSI-H/dMMR.

Estimated Treatment Costs

Enter average institutional costs.

$
$
$

Relevant mainly for locally advanced potentially converting.

$

Assumed similar for both pathways for simplicity.

Estimated Durations & Probabilities

Enter average expected values based on clinical data or assumptions.

Average duration until progression or completion (e.g., 2 years max).

Typical duration for a standard chemo regimen.

% chance surgery (planned for traditional path) is avoided due to PD-1 response/stability (mainly for locally advanced).

Simplified factor: e.g., 50% = PD-1 responders live 50% longer than chemo responders on average. Highly illustrative.

Scenario Adjustments (Optional)

If actual response < threshold, apply rebate below.

e.g., 20% rebate on total PD-1 drug cost if response < threshold.

Disclaimer & Important Limitations

This calculator provides a highly simplified economic comparison based on user inputs. It is NOT a substitute for rigorous health economic analysis, clinical judgment, or institutional financial planning.

Real-world costs and outcomes vary significantly. This model does not account for QALYs, indirect costs, detailed survival benefits, adverse event management costs, or specific payer contracts. The probability and duration estimates are illustrative.

Use this tool for conceptual discussion only. Consult with experts before making any decisions based on these results.